107. The representative of Canada welcomed the opportunity to discuss the implementation of the System and to share some thoughts on the issue of access to medicines. In response to the questions and views that had been exchanged at the review in October 2011, he updated Members on relevant legislative developments related to Canada's Access to Medicines Regime (CAMR). At the last review, Canada had advised Members that Bill C-393, which had sought to amend CAMR, had died on the Order Paper when Parliament had been dissolved. In February 2012, a similar bill, Bill C-398 had been introduced in Parliament. It had been the object of a second reading in October 2012. As was the case with Bill C-393, Bill C-398 had been introduced by a private member and not by the Government. Up-to-date information on Bill C-398, including transcripts of all debates, was available on the website of the Parliament of Canada. He recalled that his delegation had also asked a number of questions at the review in October 2010, mainly whether potential importing Members had availed themselves of pooled procurement schemes, whether Members had increased their domestic manufacturing capacities since the adoption of the 2003 Decision, and whether potential importing Members still imposed tariffs or duties on the products concerned by the 2003 Decision, as well as on other products, such as anti-malarial commodities.
